|
Mar 29
|
Mirum Pharmaceuticals (MIRM) Down 12.5% Since Last Earnings Report: Can It Rebound?
|
|
Mar 29
|
The 3 Best Biotech Stocks to Buy in Q2 2024
|
|
Mar 28
|
Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report?
|
|
Mar 27
|
Fate Therapeutics (FATE) Down 8% Since Last Earnings Report: Can It Rebound?
|
|
Mar 21
|
Why Is Halozyme Therapeutics (HALO) Up 5.3% Since Last Earnings Report?
|
|
Mar 20
|
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
|
|
Mar 14
|
Insider Sell: SVP, Chief Technical Officer Michael Labarre Sells 20,000 Shares of Halozyme ...
|
|
Mar 13
|
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
|
|
Mar 12
|
Should You Hold Halozyme Therapeutics (HALO)?
|
|
Jan 29
|
Halozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
|
|
Jan 26
|
Halozyme Therapeutics (HALO) is a Top-Ranked Growth Stock: Should You Buy?
|
|
Jan 24
|
Can Halozyme Therapeutics (HALO) Keep the Earnings Surprise Streak Alive?
|
|
Jan 16
|
Halozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
|
|
Jan 16
|
Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types
|
|
Jan 12
|
Halozyme to Host Investor Business Forum and Long-Term Outlook Call
|
|
Jan 10
|
Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock
|
|
Jan 3
|
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
|
|
Dec 15
|
Insider Sell Alert: SVP, Chief Technical Officer Michael Labarre Sells 20,000 Shares of ...
|
|
Dec 14
|
3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO)
|
|
Dec 6
|
Why Is Halozyme Therapeutics (HALO) Up 2.8% Since Last Earnings Report?
|